DMCAF News Alert Diamedica Inc (DMCAF) 0.3869 09/20/2014 20:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Diamedica Inc (DMCAF) 0.3869 $DMCAF

DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
Marketwire - Thu Aug 07, 7:05AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced the publication of its manuscript entitled, "Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus," in PLOS ONE, an international, peer-reviewed, open access, scientific journal. The manuscript can be accessed at http://dx.plos.org/10.1371/journal.pone.0103981.

DiaMedica to Present at InvestMNt Conference on August 6, 2014
Marketwire - Wed Jul 30, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota.

DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
Marketwire - Fri Jul 25, 3:30PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced that at its Annual General and Special Meeting (the "Meeting" of shareholders held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson Reimer and Thomas Wellner were re-elected as the Company's board of directors.

DiaMedica Promotes Mark Robbins to Executive Vice President
Marketwire - Thu Jul 10, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced the promotion of Mark Robbins, Ph.D., J.D., to Executive Vice President.

DiaMedica Announces Stock Option Grant
Marketwire - Tue Jul 08, 4:10PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced a grant of 150,000 stock options to Richard Pilnik, the Company's newly appointed Chairman of the Board. The options were awarded in accordance with the Stock Option Plan at an exercise price of CAD $0.69 and a term of 10 years. The options are subject to acceptance by the TSX Venture Exchange.

DiaMedica Appoints Rich Pilnik as Chairman of the Board of Directors
Marketwire - Mon Jul 07, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, announced today the appointment of Richard Pilnik as Chairman of the Company's Board of Directors.

Aon Benfield Exec: China Moving Towards Second Generation of Solvency Regime
Iris Lai - AMBest - Tue Feb 25, 11:08AM CST
China sees the need to move toward a new generation of solvency regime in light of global regulatory trends, the country's current market conditions and insurance growth over the past decade, according to Sifang Zhang, head of rating agency advisory at intermediary Aon Benfield.

Tularaemia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 18, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/5g72f2/tularaemia) has announced the addition of the "Tularaemia - Pipeline Review, H2 2013" report to their offering. 'Tularaemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tularaemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tularaemia. Scope - A snapshot of the global therapeutic scenario for Tularaemia. - A review of the Tularaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tularaemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Tularaemia Overview Therapeutics Development Pipeline Products for Tularaemia - Overview Pipeline Products for Tularaemia - Comparative Analysis Tularaemia - Therapeutics under Development by Companies Tularaemia - Therapeutics under Investigation by Universities/Institutes Tularaemia - Pipeline Products Glance Tularaemia - Products under Development by Companies Tularaemia - Products under Investigation by Universities/Institutes Tularaemia - Companies Involved in Therapeutics Development Tetraphase Pharmaceuticals Inc. Tularaemia - Therapeutics Assessment Drug Profiles gentamicin sulfate - Drug Profile Tularaemia Vaccine - Drug Profile TP-271 - Drug Profile Lm-Tularemia - Drug Profile Recombinant Tularemia Vaccine - Drug Profile Vaccine For Tularemia - Drug Profile DM-204 - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Nanotherapeutics, Inc. Aduro BioTech, Inc. DiaMedica Inc. Protein Potential, LLC EpiVax, Inc. Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5g72f2/tularaemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

2013 Report on the International Capnography Market 2012 - Forecasts to 2016
M2 - Mon Jan 13, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/g7h4gv/global) has announced the addition of the "2013 Report on the International Capnography Market 2012 - Forecasts to 2016" report to their offering. Advancements in capnography technology are allowing critical care providers to have a more accurate way of measuring CO2 in critical care patients. Although healthcare professionals have experienced major difficulties and limitations when using Mainstream and Sidestream capnography over the past few years, the latest Microstream capnography technology is expected to overcome those drawbacks. Microstream technology helps care providers monitor both intubated and non-intubated patients. Devices based on this technology can operate in extremely humid environments, in homecare, ambulatory services, and in hospitals. Microstream devices also offer improved moisture management to eliminate problems caused by blocked sample lines. One of the major growth drivers is the tremendous advancements in technology being made in the form of innovations that have led to the development of new-generation capnography devices. For example, Oridion's Microstream technology created a revolution in the Global Capnography market. Moreover, potential users in the APAC region are also expected to boost the market during the forecast period. These factors in combination with others are expected to drive the growth of the Global Capnography market during the forecast period. The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are CAS Medical Systems Inc., Diamedica Inc., Dragerwerk AG & Co. KGaA, GE Healthcare Ltd., Ivy Biomedical Systems Inc., Medtronic Inc., Nihon Kohden Corp. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - CAS Medical Systems - Covidien - Diamedica - Dragerwerk AG & Co. KGaA - GE Healthcare - Ivy Biomedical Systems - Medtronic - Nihon Kohden - Nonin Medical - OSI Systems - Opto Circuits (India) - Philips Healthcare - Smiths Medical - Triton Electronics - Weinmann Gerate fur Medizin - Welch Allyn Inc. For more information visit http://www.researchandmarkets.com/research/g7h4gv/global

DiaMedica Inc. Announces Results of Annual General and Special Meeting
Marketwire - Fri Dec 20, 4:52PM CST
DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual General and Special Meeting (the "Meeting" of shareholders of DiaMedica held on December 16, 2013, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were re-elected as the board of directors of DiaMedica.

Influenza - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Influenza
M2 - Wed Sep 04, 11:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zj34n7/influenza) has announced the addition of the "Influenza - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Influenza - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Influenza. - A review of the Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Influenza pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 4SC AG - AIMM Therapeutics B.V. - Amarillo Biosciences, Inc. - BioAlliance Pharma SA - Biotron Limited - CEL-SCI Corporation - DiaMedica Inc. - Evolva SA - Functional Genetics, Inc. - Generex Biotechnology Corporation - GlaxoSmithKline plc - Green Cross Corporation - Hawaii Biotech, Inc. - Inovio Biomedical Corporation - Johnson & Johnson - Novartis AG - Novavax, Inc. - Okairos - Panacea Biotec Limited - PaxVax - PepTcell Limited - Quantum Pharmaceuticals - Romark Laboratories, L.C. - Sanofi-Aventis - Trellis Bioscience, Inc. - UMN Pharma Inc. - Vivaldi Biosciences Inc. - Wittycell S.A.S. - XOMA Ltd. - Zosano Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/zj34n7/influenza About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DiaMedica Issues Stock Option Grant
Marketwire - Wed Jun 26, 5:23AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), announces that the Board of Directors has granted options to purchase 525,000 common shares of the Corporation to certain of its officers and directors. The options were issued at an exercise price of $1.07 per share for a ten-year term.

Pancreatic Cancer - Pipeline Review, H1 2013 Gives a Snapshot of the Global Therapeutic Scenario for Pancreatic Cancer
M2 - Wed Jun 05, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g6cvrj/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A review of the Pancreatic Cancer products under dev




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 106

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 154

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 81

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 10

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 117

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 97

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 0

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Labcorp's Brazil Trial Push Has Promise and Plenty to Prove

Updated Category News Views 24

Brazilian clinical-trial kit deliveries may soon spend less time tangled in international shipping. That is the practical heart of Labcorp's newly announced collaboration with Grupo Fleury, and frankly, practical is plenty good in this business. Labcorp plans to begin assembling clinical-trial kits locally in Brazil in early 2027, then add laboratory operations by the end...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 31

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 50

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading

Top 5 Most Recently Viewed Articles

The Exclusion of XRP from Trump's Crypto Reserve Explained

Updated Category News Views 679

Understanding the Strategic Crypto Reserve Exclusion The cryptocurrency world was recently shaken when President Donald Trump issued an executive order that left notable omissions. Among these was XRP, a digital asset that Ripple and its supporters had hoped to see included in a U.S. sovereign crypto reserve. The Ripple Effects of Trump's Order After investing heavily in...

Continue Reading
UKG Stands Out as a Top Leader in Workforce Management Solutions

Updated Category News Views 168

UKG Secures Top Spot in Workforce Management UKG, a leading provider in HR, payroll, workforce management, and cultural solutions, has recently earned recognition for its exceptional contributions to the workforce management field. The company has been named a Leader in the NelsonHall New World Workforce Management 2024 evaluation, showcasing its strong performance across...

Continue Reading
Zillow Unveils Innovative AI Virtual Staging for Listings

Updated Category News Views 283

Zillow Introduces AI-Powered Virtual Staging In an exciting development for real estate, Zillow has recently launched an innovative feature known as Virtual Staging. This tool harnesses the power of artificial intelligence to enhance how listings are showcased, making the home-buying experience even more engaging for potential buyers. Creating a Visual Experience for Home...

Continue Reading
Balchem Corporation: Innovating Health and Nutrition Solutions

Updated Category News Views 296

Balchem Corporation's Upcoming Conference Presentation Balchem Corporation, a prominent global manufacturer known for its specialty ingredients aimed at health and nutrition markets, is set to make a significant presentation at an upcoming virtual conference. The CJS Securities New Ideas for the New Year Virtual Conference will feature notable company figures, including...

Continue Reading
Projected Growth of Cottonseed Oilseed Processing Market

Updated Category News Views 85

Overview of Cottonseed Oilseed Processing Market Growth The cottonseed oilseed processing market is experiencing significant growth, projected to reach $7.7 billion within a decade, showcasing a compound annual growth rate (CAGR) of 6.8%. The increasing demand for vegetable oils, primarily for their versatility and cost-effectiveness, plays a crucial role in this market's...

Continue Reading